| Literature DB >> 29042390 |
Anne Holm1, Gloria Cordoba1, Tina Møller Sørensen2, Lisbeth Rem Jessen2, Niels Frimodt-Møller3, Volkert Siersma1, Lars Bjerrum1.
Abstract
OBJECTIVES: To investigate the effect of adding point-of-care (POC) susceptibility testing to POC culture on appropriate use of antibiotics as well as clinical and microbiological cure for patients with suspected uncomplicated urinary tract infection (UTI) in general practice.Entities:
Keywords: antibiotics; culture media; microbiological diagnosis; point-of-care testing; urinary tract infections
Mesh:
Substances:
Year: 2017 PMID: 29042390 PMCID: PMC5652479 DOI: 10.1136/bmjopen-2017-018028
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Inclusion flow chart.
Distribution of baseline data between the randomisation groups
| Culture and susceptibility, n (%) | Culture only, n (%) | p | |
| Age groups | |||
| Age below 50 years | 105 (55) | 83 (48) | NS |
| Age 50 years or above | 86 (45) | 89 (52) | NS |
| Number of days with symptoms | |||
| Symptoms for less than 3 days | 77 (41) | 67 (40) | NS |
| Symptoms 3 days or more | 109 (59) | 101 (60) | NS |
| Key symptoms (dysuria, frequency, urge) | |||
| One or two key symptoms | 75 (40) | 67 (40) | NS |
| Three key symptoms | 111 (60) | 100 (60) | NS |
| Complicating factors | |||
| Any complicating factor | 43 (26) | 62 (38) | 0.0209 |
| Elderly above 65 years | 34 (20) | 50 (29) | 0.0496 |
| Recurrent UTI (>3 past year) | 11 (6) | 6 (4) | NS |
| Uncomplicated diabetes | 11 (6) | 17 (10) | NS |
| Reference culture and susceptibility test | |||
| Significant growth of uropathogens (UTI) | 100 (62) | 104 (64) | NS |
| Trimethroprim resistance | 27 (26) | 21 (20) | NS |
| Sulfamethizole resistance | 29 (29) | 24 (24) | NS |
| Nitrofurantoine resistance | 3 (3) | 3 (4) | NS |
| Mecillinam resistance (pivmecillinam) | 15 (14) | 9 (9) | NS |
Numbers are total numbers with percentages in brackets.
NS, non-significant; UTI, urinary tract infection.
Comparison of primary and secondary outcomes between the randomisation groups
| n | OR (95% CI) | p | |
| Unadjusted analysis | |||
| Odds for appropriate prescribing if culture only | 341 | 1.44 (1.03 to 1.99) | 0.0311 |
| Odds for being symptom free on day 5 if culture-only | 308 | 0.91 (0.56 to 1.49) | NS |
| Odds for no significant bacteriuria on day 14 if culture only | 144 | 1.15 (0.62 to 2.13) | NS |
| Adjusted for complicating factors | |||
| Odds for appropriate prescribing if culture only | 324 | 1.65 (1.12 to 2.42) | 0.0112 |
| Odds for being symptom-free on day five if culture only | 293 | 0.89 (0.55 to 1.44) | NS |
| Odds for no significant bacteriuria on day 14 if culture only | 140 | 1.23 (0.64 to 2.38) | NS |
| Subgroup analysis (unadjusted) | |||
| Odds for appropriate prescribing for young patients without comorbidities if culture only | 222 | 1.79 (1.06 to 3.02) | 0.0300 |
| Odds for appropriate prescribing for patients that were elderly, had diabetes or had recurrent UTI if culture only | 102 | 1.37 (0.78 to 2.41) | NS |
OR, Odds for having a positive outcome if randomised to culture-only (ID Flexicult) compared with culture and susceptibility testing (Flexicult SSI-Urinary Kit).
NS, non-significant; UTI, urinary tract infection.
Reasons for appropriate and inappropriate choice of treatment and distribution of patients between groups
| Culture and susceptibility, n (%) | Culture only, n (%) | |
| Appropriate choice of treatment | 120 (67) | 121 (75) |
| UTI and first-line antibiotic and pathogen susceptible | 85 (47) | 90 (56) |
| UTI, second-line antibiotic and pathogen susceptible and first-line antibiotic impossible due to allergies or resistance | 0 (0) | 0 (0) |
| No UTI and no antibiotic | 35 (20) | 31 (19) |
| Inappropriate choice of treatment | 59 (33) | 41 (25) |
| UTI and no antibiotic | 13 (7) | 7 (4) |
| UTI and antibiotic but uropathogen not susceptible to antibiotic | 10 (6) | 7 (4) |
| UTI and inappropriate second-line antibiotic | 3 (2) | 0 (0) |
| No UTI and antibiotic | 33 (18) | 27 (17) |
The overall difference was significant as shown in table 2, but none of the individual differences was significant.
NS, non-significant; UTI, urinary tract infection.
Figure 2Cure rates for the two groups. The level of the coloured lines indicates the proportion of patients still having symptoms. Day 0 is the evening of the day of the consultation. The first vertical grey line indicates initiation of treatment (the morning after the consultation); the second vertical grey line indicates the data used for calculation of the secondary outcome: clinical cure on day 5 (4 days after consultation).